性视界传媒

YONGIN, South Korea 性视界传媒� GC Biopharma, a South Korean pharmaceutical company, announced that its U.S. subsidiary, ABO Holdings, has received FDA approval for its plasma collection center located in Calexico, California.

Following the successful U.S. launch of ALYGLO (immune globulin intravenous, human-stwk) 10% Liquid, GC Biopharma acquired ABO Holdings in January to support the product's expected mid- to long-term revenue growth, the company said in a press release.

With this approval, ABO Holdings is now operating all six plasma collection centers性视界传媒攖wo each in California, Utah, and New Jersey. The company plans to ramp up donor recruitment efforts in the second quarter, setting the stage for substantial business growth in the second half of the year.

Additionally, ABO Holdings is on track to complete construction of two new plasma centers in Texas and aims to obtain FDA approval for both facilities by 2027. GC Biopharma anticipates gradual growth in its source plasma business starting in the latter half of this year, the company said.

性视界传媒淲ith all six FDA-approved plasma centers now operational, the company is well-positioned to achieve sustainable revenue growth for Alyglo,性视界传媒� said Eun-chul Huh, President and CEO of GC Biopharma. 性视界传媒淭his milestone represents a significant contribution to our overall business profitability.性视界传媒�

GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yong-in, South Korea. The company has over half a century of experience in the development and manufacturing of plasma derivatives and vaccines and is expanding its global presence with the successful US market entry of Alyglo in 2024.

The company said it continues to drive innovation by leveraging its core R&D capabilities in the engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platforms to develop therapeutics for the field of rare diseases as well as I&I (Immunology & Inflammation).

To learn more about the company, visit